Innovent's PECONDLE Shows Strong Efficacy and Safety in Phase 3 Trial for Psoriasis

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Dec 09 2025

0mins

Source: NASDAQ.COM

Study Results: Innovent Biologics' PECONDLE (picankibart injection) met primary and key secondary efficacy endpoints in the Phase 3 CLEAR-2 study for moderate-to-severe plaque psoriasis, showing high maintenance rates of PASI 90 response at Week 56.
Efficacy and Safety: The treatment demonstrated durable efficacy with significant improvements in various psoriasis severity measures and maintained a favorable safety profile without new safety signals.
Treatment Comparison: Patients receiving maintenance treatment with picankibart had significantly better outcomes compared to those who underwent treatment withdrawal, highlighting its disease-modifying potential.
Market Approval: PECONDLE is the first China-developed IL-23p19 monoclonal antibody, receiving market approval from the NMPA in November 2025 for adult patients eligible for systemic therapy.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.